{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:18:01Z","timestamp":1791321481900,"version":"4.3.1"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100003157","name":"Myasthenia Gravis Foundation of America Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003157","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jneuroim.2024.578464","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T19:06:00Z","timestamp":1728500760000},"page":"578464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients"],"prefix":"10.1016","volume":"396","author":[{"given":"Yingkai","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongqiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyi","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2024.578464_bb0005","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cyto.2017.05.008","article-title":"Ablation of IL-17 expression moderates experimental autoimmune myasthenia gravis disease severity","volume":"96","author":"Aguilo-Seara","year":"2017","journal-title":"Cytokine"},{"key":"10.1016\/j.jneuroim.2024.578464_bb0010","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.neurol.2018.01.377","article-title":"Clinical efficacy of tacrolimus for treating myasthenia gravis and its influence on lymphocyte subsets","volume":"175","author":"Bao","year":"2019","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0015","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.imbio.2016.06.012","article-title":"A novel infection- and inflammation-associated molecular signature in peripheral blood of myasthenia gravis patients","volume":"221","author":"Barzago","year":"2016","journal-title":"Immunobiology"},{"key":"10.1016\/j.jneuroim.2024.578464_bb0020","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG composite: a valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2024.578464_bb0025","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.immuni.2014.10.004","article-title":"T follicular helper cell differentiation, function, and roles in disease","volume":"41","author":"Crotty","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.jneuroim.2024.578464_bb0030","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.cell.2015.11.009","article-title":"Single-cell genomics unveils critical regulators of Th17 cell pathogenicity","volume":"163","author":"Gaublomme","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.jneuroim.2024.578464_bb0035","first-page":"8","article-title":"Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy","author":"Golubovskaya","year":"2016","journal-title":"Cancers"},{"key":"10.1016\/j.jneuroim.2024.578464_bb0040","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1471-2377-11-97","article-title":"A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis","volume":"11","author":"Heckmann","year":"2011","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0045","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1182\/blood-2009-10-233585","article-title":"NFAT pulls the strings during CD4+ T helper cell effector functions","volume":"115","author":"Hermann-Kleiter","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2024.578464_bb0050","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ni.1993","article-title":"Fate mapping of IL-17-producing T cells in inflammatory responses","volume":"12","author":"Hirota","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0055","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/s41467-017-01571-8","article-title":"Transcriptional signature of human pro-inflammatory TH17 cells identifies reduced IL10 gene expression in multiple sclerosis","volume":"8","author":"Hu","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0060","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.bbrc.2019.06.094","article-title":"Exacerbation of pathogenic Th17-cell-mediated cutaneous graft-versus-host-disease in human IL-1beta and IL-23 transgenic humanized mice","volume":"516","author":"Ito","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0065","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ene.13189","article-title":"Adequate tacrolimus concentration for myasthenia gravis treatment","volume":"24","author":"Kanai","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0070","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1185\/030079904125004385","article-title":"Low-dose tacrolimus treatment in thymectomised and steroid-dependent myasthenia gravis","volume":"20","author":"Kawaguchi","year":"2004","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2019.04.006","article-title":"Fate-mapping of GM-CSF expression identifies a discrete subset of inflammation-driving T helper cells regulated by cytokines IL-23 and IL-1beta","volume":"50","author":"Komuczki","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.jneuroim.2024.578464_bb0080","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3908061","article-title":"The role of IL-17 and related cytokines in inflammatory autoimmune diseases","volume":"2017","author":"Kuwabara","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0085","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0090","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni.2416","article-title":"Induction and molecular signature of pathogenic TH17 cells","volume":"13","author":"Lee","year":"2012","journal-title":"Nat. Immunol."},{"issue":"Suppl. 1","key":"10.1016\/j.jneuroim.2024.578464_bb0095","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1007\/s10875-014-0040-5","article-title":"Unexpected targets and triggers of autoimmunity","volume":"34","author":"Lee","year":"2014","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0100","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.expneurol.2018.11.006","article-title":"Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients","volume":"312","author":"Li","year":"2019","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577279","article-title":"Imbalance in T follicular helper cells producing IL-17 promotes pro-inflammatory responses in MuSK antibody positive myasthenia gravis","volume":"345","author":"Li","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0110","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jneuroim.2012.12.001","article-title":"Expansion of circulating counterparts of follicular helper T cells in patients with myasthenia gravis","volume":"256","author":"Luo","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108492","article-title":"Circulating Th1\/17 cells serve as a biomarker of disease severity and a target for early intervention in AChR-MG patients","volume":"218","author":"Ma","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0120","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00228-019-02803-0","article-title":"Multiple genetic factors affecting the pharmacokinetic and pharmacodynamic processes of tacrolimus in Chinese myasthenia gravis patients","volume":"76","author":"Meng","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0125","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.WNL.0000094122.88929.0B","article-title":"Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability","volume":"61","author":"Meriggioli","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2024.578464_bb0130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jns.2010.09.033","article-title":"Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis","volume":"300","author":"Minami","year":"2011","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0135","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1017\/S0031182017000245","article-title":"The antimalarial action of FK506 and rapamycin: evidence for a direct effect on FK506-binding protein PfFKBP35","volume":"144","author":"Monaghan","year":"2017","journal-title":"Parasitology"},{"key":"10.1016\/j.jneuroim.2024.578464_bb0140","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.iy.07.040189.001045","article-title":"TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties","volume":"7","author":"Mosmann","year":"1989","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0145","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2169\/internalmedicine.47.0513","article-title":"Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus","volume":"47","author":"Nagaishi","year":"2008","journal-title":"Intern. Med."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0150","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000085833","article-title":"Efficacy of low-dose FK506 in the treatment of Myasthenia gravis--a randomized pilot study","volume":"53","author":"Nagane","year":"2005","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0155","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/mus.21462","article-title":"Factors associated with response to calcineurin inhibitors in myasthenia gravis","volume":"41","author":"Nagane","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2024.578464_bb0160","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1212\/01.WNL.0000160392.32894.6D","article-title":"Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis","volume":"64","author":"Ponseti","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2024.578464_bb0165","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1196\/annals.1405.000","article-title":"Tacrolimus for myasthenia gravis: a clinical study of 212 patients","volume":"1132","author":"Ponseti","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0170","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/mus.22070","article-title":"Increased serum interleukin-17 levels in patients with myasthenia gravis","volume":"44","author":"Roche","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2024.578464_bb0175","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00054725-199911000-00009","article-title":"Th1\/Th2 cells","volume":"5","author":"Romagnani","year":"1999","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0180","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jneuroim.2005.09.001","article-title":"Altered expression of chemokine receptor CXCR5 on T cells of myasthenia gravis patients","volume":"170","author":"Saito","year":"2005","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0185","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-immunol-042718-041717","article-title":"Regulatory T cells and human disease","volume":"38","author":"Sakaguchi","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0190","first-page":"40","article-title":"CD4+ T-cell produced IL17 is essential for loss of B-cell tolerance in experimental autoimmune myasthenia gravis (EAMG)","volume":"21","author":"Schaffert","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0195","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.immuni.2015.12.011","article-title":"Circulating HIV-specific Interleukin-21+CD4+ T cells represent peripheral Tfh cells with antigen-dependent helper functions","volume":"44","author":"Schultz Bruce","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.jneuroim.2024.578464_bb0200","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev.iy.12.040194.003223","article-title":"Acquisition of lymphokine-producing phenotype by CD4+ T cells","volume":"12","author":"Seder","year":"1994","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0205","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nri.2017.50","article-title":"The dichotomous nature of T helper 17 cells","volume":"17","author":"Stockinger","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0210","doi-asserted-by":"crossref","first-page":"A3.B.1","DOI":"10.1002\/0471142735.ima03bs111","article-title":"Trypan blue exclusion test of cell viability","volume":"111","author":"Strober","year":"2015","journal-title":"Curr. Protoc. Immunol."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0215","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00005-015-0344-z","article-title":"The role of IL-17 and Th17 lymphocytes in autoimmune diseases","volume":"63","author":"Tabarkiewicz","year":"2015","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0220","doi-asserted-by":"crossref","first-page":"718","DOI":"10.4049\/jimmunol.143.2.718","article-title":"The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes","volume":"143","author":"Tocci","year":"1989","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0225","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2174\/187152812800392805","article-title":"The IL23\/Th17 pathway as a therapeutic target in chronic inflammatory diseases","volume":"11","author":"Toussirot","year":"2012","journal-title":"Inflamm. Allergy Drug Targets"},{"key":"10.1016\/j.jneuroim.2024.578464_bb0230","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/mus.10285","article-title":"Effects of FK506 on myasthenia gravis patients with high interleukin-2 productivity in peripheral blood mononuclear cells","volume":"27","author":"Utsugisawa","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2024.578464_bb0235","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jaut.2018.11.005","article-title":"Il-23\/Th17 cell pathway: a promising target to alleviate thymic inflammation maintenance in myasthenia gravis","volume":"98","author":"Villegas","year":"2019","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0240","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","article-title":"Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays","volume":"48","author":"Vincent","year":"1985","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2024.578464_bb0245","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jocn.2019.02.004","article-title":"Effectiveness and safety of tacrolimus therapy for myasthenia gravis: a single arm meta-analysis","volume":"63","author":"Wang","year":"2019","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0250","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/ana.410150615","article-title":"Azathioprine in the treatment of myasthenia gravis","volume":"15","author":"Witte","year":"1984","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0255","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cyto.2015.06.011","article-title":"Elevated plasma interleukin-17A in a subgroup of myasthenia gravis patients","volume":"78","author":"Xie","year":"2016","journal-title":"Cytokine"},{"key":"10.1016\/j.jneuroim.2024.578464_bb0260","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00005-015-0362-x","article-title":"Targeting Th17 effector cytokines for the treatment of autoimmune diseases","volume":"63","author":"Yamagata","year":"2015","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0265","series-title":"Corticosteroid Adverse Effects","author":"Yasir","year":"2022"},{"key":"10.1016\/j.jneuroim.2024.578464_bb0270","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaut.2013.12.005","article-title":"Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis","volume":"52","author":"Yi","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2019.113146","article-title":"Inhibition of the transcription factor ROR-\u03b3 reduces pathogenic Th17 cells in acetylcholine receptor antibody positive myasthenia gravis","volume":"325","author":"Yi","year":"2020","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0280","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.4049\/jimmunol.1500725","article-title":"Augmentation of circulating follicular helper T cells and their impact on autoreactive B cells in myasthenia gravis","volume":"197","author":"Zhang","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0285","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.intimp.2010.12.012","article-title":"Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis","volume":"11","author":"Zhao","year":"2011","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0290","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/1756285617721092","article-title":"Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China","volume":"10","author":"Zhou","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.jneuroim.2024.578464_bb0295","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21218011","article-title":"CD4 T Helper Cell Subsets and Related Human Immunological Disorders","volume":"21","author":"Zhu","year":"2020","journal-title":"Int. J. Mol. Sci."}],"updated-by":[{"DOI":"10.1016\/j.jneuroim.2025.578526","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000}}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572824001838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572824001838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T04:22:35Z","timestamp":1741148555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572824001838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":59,"alternative-id":["S0165572824001838"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578464","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jneuroim.2025.578526","asserted-by":"object"}]},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in AChR-myasthenia gravis patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578464","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"578464"}}